Atrion Corp.

  • Market Cap: Micro Cap
  • Industry: Medical Specialties
  • ISIN: US0499041053
USD
459.92
0.26 (0.06%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Atrion Corp. stock-summary
stock-summary
Atrion Corp.
Medical Specialties
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company's medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in areas, such as anesthesia and oncology. Its cardiovascular product, MPS2 Myocardial Protection System (MPS2), is the system used in open-heart surgery that delivers fluids and medications, mixes critical drugs and controls temperature, pressure and other variables. The Company manufactures specialized medical devices that disinfect contact lenses. Its other medical and non-medical product lines consist of instrumentation and associated disposables.
Company Coordinates stock-summary
Company Details
1 Allentown Pkwy , ALLEN TX : 75002-4206
stock-summary
Tel: 1 972 39098001 972 3909800
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 45 Schemes (23.11%)

Foreign Institutions

Held by 61 Foreign Institutions (4.34%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Emile Battat
Chairman of the Board, Chairman of the Board of Halkey-Roberts Corporation
Mr. Ronald Spaulding
Lead Independent Director
Mr. Preston Athey
Independent Director
Mr. Hugh Morgan
Independent Director
Mr. John Stupp
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
49 Million
(Quarterly Results - Jun 2024)
Net Profit:
0 Million
stock-summary
Industry

Medical Specialties

stock-summary
Market cap

USD 809 Million (Micro Cap)

stock-summary
P/E

60.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

100.53%

stock-summary
Debt Equity

-0.07

stock-summary
Return on Equity

5.61%

stock-summary
Price to Book

3.39